In an immunosuppressed post‑CAR‑T patient with persistent cerebral and cerebellar enhancing lesions and a new left basal ganglia focus on repeat MRI, favoring cryptococcal infection over myeloma involvement and no mass effect or midline shift, is a stereotactic brain biopsy feasible, should lymphoma be considered, and what additional tests should be ordered to distinguish infection from lymphoma?

Brain Biopsy is Feasible and Should Be Strongly Considered in This Post-CAR-T Patient

In this immunosuppressed post-CAR-T patient with persistent enhancing brain lesions and a new basal ganglia focus, stereotactic brain biopsy is both feasible and clinically indicated to definitively distinguish between cryptococcal infection, post-transplant lymphoproliferative disorder (PTLD), and other diagnoses—particularly given the absence of mass effect or midline shift.

Why Biopsy is Critical Here

The clinical scenario presents a diagnostic dilemma where imaging alone cannot reliably differentiate between:

• Cryptococcal cryptococcomas (the radiologic favored diagnosis)
• CNS post-transplant lymphoproliferative disorder (PTLD) or lymphoma recurrence
• Other opportunistic infections in this profoundly immunosuppressed state

Lymphoma Concern is Legitimate and Must Be Addressed

Yes, you should absolutely be concerned about lymphoma/PTLD in this post-CAR-T patient. Primary CNS PTLD presents with ring-enhancing lesions that are typically supratentorial and can be solitary or multiple—clinically and radiologically indistinguishable from cryptococcomas 1. Post-CAR-T patients on prolonged immunosuppression are at substantial risk for PTLD, which requires histological diagnosis via biopsy 1. The median time to PTLD diagnosis varies widely (9 months post-HSCT to 21.5 years post-solid organ transplant), but CAR-T recipients fall into a high-risk category 1.

Biopsy Indications from Guidelines

The IDSA cryptococcal guidelines explicitly recommend biopsy for:

• Large (≥3 cm) accessible lesions with mass effect
• Enlarging lesions not explained by IRIS (immune reconstitution inflammatory syndrome)
• Need for tissue diagnosis when clinical picture is unclear 2

While your patient lacks mass effect, the new basal ganglia focus on repeat imaging constitutes an "enlarging/new lesion" scenario that warrants tissue diagnosis, especially when the differential includes treatable but distinct entities (fungal vs. lymphoma) 2.

Diagnostic Workup Algorithm

Immediate CSF Studies (if not already done comprehensively):

1. Cryptococcal antigen (CrAg) in CSF and serum - highest yield test
2. CSF fungal culture - gold standard but takes time
3. CSF opening pressure - critical for cryptococcal management (elevated in most cases) 2
4. CSF cytology with flow cytometry - to evaluate for lymphoma
5. CSF PCR for Cryptococcus - rapid molecular confirmation 3
6. Repeat CSF sampling if initial studies negative - false-negative CSF studies occur even with active disease 3, 4

Critical caveat: Up to 47% of cryptococcal meningitis cases have normal CT scans, and 10% have normal MRIs 4, 5. Serial CSF sampling with targeted mycological testing is essential in subacute presentations with nondiagnostic initial studies 6, 3.

Serum Studies:

• Serum cryptococcal antigen - highly sensitive, can be positive when CSF is negative
• Serum EBV PCR - PTLD is typically EBV-driven 1
• Beta-D-glucan and galactomannan - for other invasive fungal infections
• CD4 count - assess degree of immunosuppression (late primary immunodeficiency can occur) 7

Advanced Imaging:

• MRI with contrast (if not already done) - contrast-enhancing lesions in basal ganglia (22%), meningeal enhancement (56%), ependymal enhancement (24%), and dilated perivascular spaces (24%) are characteristic of cryptococcosis 4
• Follow-up MRI in 2-4 weeks if empiric antifungal therapy initiated - failure to reduce lesion size after 4 weeks of therapy is a biopsy indication 2

Pulmonary Evaluation:

• Chest CT - cryptococcosis often has pulmonary involvement; nodules or infiltrates suggest disseminated disease 6, 3
• Bronchoscopy with BAL if pulmonary lesions present - can provide diagnostic material

Biopsy Approach

Stereotactic brain biopsy is the preferred method given multiple lesions and need for precise targeting 1. The procedure is safe in the absence of mass effect or midline shift. Tissue should be sent for:

• Fungal culture and histopathology (GMS, PAS stains for Cryptococcus)
• Bacterial and mycobacterial cultures
• Histopathology with immunohistochemistry (CD20, CD3, EBV-encoded RNA [EBER] in situ hybridization for PTLD) 1
• Molecular studies (broad-range PCR if available)

Management Considerations While Awaiting Diagnosis

If Cryptococcosis is Confirmed or Highly Suspected:

Induction therapy for CNS cryptococcosis in immunosuppressed non-HIV patients:

• Liposomal amphotericin B (3-4 mg/kg/day IV) or AmBd (0.7-1 mg/kg/day IV) PLUS flucytosine (100 mg/kg/day PO in 4 divided doses) for at least 2 weeks (ideally 4-6 weeks for cryptococcomas) 2
• If flucytosine unavailable: AmBd (1 mg/kg/day) for 4-6 weeks or AmBd (0.7 mg/kg/day) + fluconazole (800 mg/day) for 4-6 weeks 2

Consolidation therapy:

• Fluconazole 400-800 mg/day PO for 6-18 months 2

Critical management points:

• Monitor and manage elevated intracranial pressure aggressively with serial lumbar punctures (opening pressure typically elevated) 2
• Corticosteroids may be considered for mass effect and surrounding edema from cryptococcomas, but use cautiously as they can worsen infection 2
• Surgery (open or stereotactic debulking) is indicated for large (≥3 cm) accessible lesions with mass effect or failure to respond to 4 weeks of antifungal therapy 2

If PTLD/Lymphoma is Confirmed:

• Reduce or discontinue immunosuppression (coordinate with oncology/transplant team)
• Rituximab is first-line for CD20+ PTLD 1
• Zanubrutinib shows promise as a safe and effective option 1
• Whole-brain radiation + rituximab for refractory cases 1
• Surgical resection if feasible for accessible lesions 1

Infection Risk in Post-CAR-T Patients

This patient population faces exceptionally high infection risk:

• Any-grade infections occur in 40-80% of CAR-T recipients 8
• Grade ≥3 infections exceed 50% in many cohorts 8
• Fungal infections (including Cryptococcus), CMV reactivation, and PJP are well-documented complications 8
• Risk factors: neutropenia, corticosteroid/tocilizumab exposure (for CRS management), hypogammaglobulinemia 8

Prophylaxis gaps: Ensure patient is on:

• PJP prophylaxis (trimethoprim-sulfamethoxazole or alternative)
• Antiviral prophylaxis (acyclovir/valacyclovir)
• Consider IVIG replacement if hypogammaglobulinemic 8

Common Pitfalls to Avoid

1. Assuming imaging findings are diagnostic - cryptococcomas and PTLD are radiologically identical; tissue diagnosis is essential
2. Accepting a single negative CSF study - repeat lumbar punctures increase diagnostic yield 6, 3
3. Delaying biopsy due to perceived "high risk" - in the absence of mass effect, stereotactic biopsy is safe and changes management
4. Undertreating cryptococcal disease - basal ganglia involvement requires prolonged therapy (6-18 months consolidation) and can cause irreversible neurological sequelae if inadequately treated 6
5. Ignoring pulmonary disease - disseminated cryptococcosis requires evaluation of lungs; pulmonary nodules can provide easier biopsy targets 6, 3

Bottom Line

Proceed with stereotactic brain biopsy to obtain definitive tissue diagnosis. While awaiting biopsy results, complete the diagnostic workup outlined above (CSF studies, serum CrAg, EBV PCR, chest imaging). If biopsy is delayed or declined, empiric antifungal therapy with liposomal amphotericin B plus flucytosine is reasonable given the radiologic suspicion for cryptococcosis, but this approach risks missing PTLD/lymphoma, which requires entirely different management. The new basal ganglia lesion on repeat imaging is a red flag that demands histological clarification 2.